Literature DB >> 30249716

Reply to Sorooshian and Snow, "Is Alternate-Day Therapeutic Drug Monitoring in the Intensive Care Unit Not Intensive Enough?"

A Fournier1,2, P Eggimann3, O Pantet3, J L Pagani3, E Dupuis-Lozeron4, A Pannatier1, F Sadeghipour1,2, P Voirol1,2, Y-A Que5.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30249716      PMCID： PMC6153816          DOI： 10.1128/AAC.01343-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study.

Authors:  Bhavik M Patel; Jennifer Paratz; Natalie C See; Michael J Muller; Michael Rudd; David Paterson; Scott E Briscoe; Jacobus Ungerer; Brett C McWhinney; Jeffrey Lipman; Jason A Roberts
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

Review 2.  A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics.

Authors:  Jason A Roberts; Steven Webb; David Paterson; Kwok M Ho; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

3.  Is Alternate-Day Therapeutic Drug Monitoring in the Intensive Care Unit Not Intensive Enough?

Authors:  Parviz Sorooshian; Timothy A C Snow
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 4.  Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.

Authors:  Erlangga Yusuf; Herbert Spapen; Denis Piérard
Journal:  J Crit Care       Date:  2014-08-07       Impact factor: 3.425

5.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.

Authors:  Jason A Roberts; Marta Ulldemolins; Michael S Roberts; Brett McWhinney; Jacobus Ungerer; David L Paterson; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2010-08-03       Impact factor: 5.283

6.  Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit.

Authors:  P Voirol; Y-A Que; A Fournier; P Eggimann; O Pantet; J L Pagani; E Dupuis-Lozeron; A Pannatier; F Sadeghipour
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

7.  Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.

Authors:  Anne Fournier; Philippe Eggimann; Jean-Luc Pagani; Jean-Pierre Revelly; Laurent A Decosterd; Oscar Marchetti; André Pannatier; Pierre Voirol; Yok-Ai Que
Journal:  Burns       Date:  2015-02-10       Impact factor: 2.744

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.